<DOC>
	<DOCNO>NCT00520806</DOCNO>
	<brief_summary>Different dos relaxin compare placebo determine efficacy safety treatment patient hospitalize acute heart failure</brief_summary>
	<brief_title>Efficacy Safety Relaxin Treatment Acute Heart Failure</brief_title>
	<detailed_description>This international , randomize , double-blind , placebo-controlled , Phase II/III trial intravenous recombinant relaxin treatment sign symptoms patient hospitalize acute decompensated heart failure . The Phase II pilot study complete ; Phase III main portion trial ongoing .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Hospitalized acute heart failure Dyspnea rest minimal exertion Pulmonary congestion Able provide inform consent Systolic blood pressure &gt; 125 mmHg Impaired renal function define eGFR 3075 mL/min/1.73m2 Use IV therapy acute heart failure Fever sepsis Recent major neurologic event Recent major surgery Recent acute coronary syndrome Other recent investigational drug use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Renal dysfunction</keyword>
	<keyword>Relaxin</keyword>
	<keyword>Vasodilator</keyword>
</DOC>